Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B. The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name "Heptodin" in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.
By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules. Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017. The market is dominated by GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.
Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China's Lamivudine market will continue to grow.
Topics Covered:
- Development environment of China's Lamivudine market
- Size of China's Lamivudine market
- Competition pattern of China's Lamivudine market
- Prices of Lamivudine in China
- Driving forces and opportunities for China's Lamivudine market
- Prospect of China's Lamivudine market from 2018 to 2022
Table of Contents
Companies Mentioned
- GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.
- Wellcome Foundation
- Anhui Biochem Bio-Pharmaceutical Co., Ltd.
- Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd.
- Beijing Winsunny Pharmaceutical Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
